Senti Biosciences, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$51M
↓-47.6% -$47Mvs FY2024
Total Liabilities
$46M
↓-3.1% -$1Mvs FY2024
Equity
$6M
↓-78.2% -$20Mvs FY2024
Cash
$16M
↓-66.0% -$32Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $51M | $98M |
| Current Assets | $23M | $59M |
| Cash | $16M | $48M |
| ST Investments | $0 | $0 |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $7M | $11M |
| Non-Current Assets | $28M | $39M |
| PPE | $13M | $21M |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $15M | $18M |
| Total Liab+Eq | $51M | $73M |
| Current Liab. | $14M | $13M |
| Accounts Payable | $3M | $1M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $43K | $0 |
| Other CL | $11M | $12M |
| Non-Current Liab. | $32M | $34M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $32M | $34M |
| Equity | $6M | $26M |
| Retained Earnings | $359M | $297M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · SNTI · Comparing FY2025 vs FY2024